OmniAb, Inc. (OABI)

Market Cap	197.51M
Revenue (ttm)	23.03M
Net Income (ttm)	-63.52M
Shares Out	122.70M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	291,963
Open	1.610
Previous Close	1.610
Day's Range	1.600 - 1.670
52-Week Range	1.220 - 4.870
Beta	0.94
Analysts	Strong Buy
Price Target	6.67 (+314.36%)
Earnings Date	Aug 6, 2025

About OABI

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 114
• Stock Exchange: NASDAQ
• Ticker Symbol: OABI
• Website: https://www.omniab.com

Financial Performance

In 2024, OmniAb's revenue was $26.39 million, a decrease of -22.75% compared to the previous year's $34.16 million. Losses were -$62.03 million, 22.5% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price target is $6.67, which is an increase of 314.36% from the latest price.

Price Target

$6.67

(314.36% upside)

Analyst Consensus: Strong Buy